MELANOMA

This study compares a new drug, AVT32-DRL_PB (a biosimilar to Keytruda), with Keytruda itself in people with stage IIB/C or III melanoma that has been fully removed by surgery. About 120 adults will receive either the biosimilar or Keytruda every 3 weeks for up to 6 cycles. The g…

This study tests a new combination of drugs (SHR-1701 and famitinib) given before and after surgery for a rare type of skin cancer called mucosal melanoma. The goal is to see if this approach can help keep the cancer from coming back. About 70 adults with resectable tumors will t…

This early-stage study tests whether a new drug called HLX18 works like the approved cancer drug OPDIVO. About 174 adults with esophageal cancer, melanoma, or bladder cancer who had surgery to remove their tumors will receive either HLX18 or OPDIVO. The main goal is to compare ho…

This study tests a combination of three drugs (cemiplimab, fianlimab, and ipilimumab) given before surgery to people with stage III or IV melanoma that can be removed. The goal is to see if this approach is safe and helps shrink tumors. About 20 adults who have not had prior trea…

This study tests whether a new drug called Bmab1700 works like the approved drug Opdivo in people with melanoma (a serious skin cancer) after their tumor has been completely removed by surgery. The study will involve 120 adults with stage IIB to IV melanoma. The main goal is to c…

This study looks at whether giving immunotherapy earlier in the day can help people with advanced melanoma live longer without their cancer growing. Researchers will compare morning versus later-day infusions in 108 adults. The goal is to see if matching treatment timing with the…

This early-phase trial tests a virus called DNX-2401 that is designed to infect and destroy cancer cells in people with advanced melanoma that has spread to the brain and/or other parts of the body. The main goal is to find the safest dose and number of injections. About 50 adult…

This is the first human study of an experimental oral drug called ACC-1898 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and understand how the body processes the drug. Participants will take dail…

This study compares two versions of a support tool for young adults (ages 20-39) who have had thyroid, melanoma, or testicular cancer. One version provides cancer information only, while the other adds personalized emotional support strategies. The goal is to see if the extra sup…

This study tests a program called FOCUS, delivered through a smartphone app and telemedicine, to help people with advanced cancer manage common symptoms like trouble sleeping, worry, sadness, and fatigue. The goal is to improve quality of life and make these skills accessible to …

This study looks at whether melanoma patients who eat more fiber respond better to immunotherapy drugs. Researchers will track the fiber intake of 60 patients and see if those with a high-fiber diet have fewer recurrences or better tumor control. The goal is to understand the lin…

This study looks at how immunotherapy drugs (immune checkpoint inhibitors) might change the way the liver processes other medications. Researchers will give 80 cancer patients a mix of 7 common drugs to measure these effects. The goal is to understand and reduce side effects from…

This early-stage study tests whether inhaling the cancer drug afatinib works as well as taking it by mouth. It involves 24 healthy adult smokers who will receive both forms in separate sessions. The goal is to measure drug levels in the blood and lungs, and check for side effects…

This study is a screening survey to find people who may be eligible for one of several cancer genetics research studies at the National Cancer Institute. It is open to people of any age who have a personal or family history of certain cancers or genetic syndromes. Participants fi…